Agenda

Click on the session names below for more information, including location, speakers, and session descriptions.

---

• Sat, Apr 109
• Sun, Apr 110
• Mon, Apr 111
• Tue, Apr 112

Saturday, April 109, 2020

8:30am – 12:00pm

Strategic Planning Committee

1:00pm – 5:00pm

ISPE Board of Directors Meeting

6:00pm – 9:00pm

Board of Directors Dinner

Sunday, April 110, 2020

7:00am – 5:00pm

Registration

8:00am – 12:00pm

Introduction to Pharmacoepidemiology

8:30am – 12:00pm

2020 ICPE Scientific Program Committee

1:30pm – 5:30pm

Advanced Pharmacoepidemiology - Machine Learning in Pharmacoepidemiology

5:30pm – 7:30pm

Welcome Reception

Monday, April 111, 2020

7:30am – 5:00pm

Registration

8:15am – 9:15am

Breakfast/Posters/Exhibitors

9:15am – 9:30am

Welcome and Opening Remarks

9:30am – 11:30am

At the intersection of frailty and pharmacoepidemiology: Foundations, applications, and future directions

11:30am – 12:00pm

Break/Posters/Exhibitors

12:00pm – 1:00pm

Deprescribing and Pharmacoepidemiology - Opportunity, Power, Humility (Keynote)

1:00pm – 2:00pm

Lunch/Posters/ Exhibitors

2:00pm – 3:30pm

Student Oral Session I

2:00pm – 3:30pm

Using Drug Utilization Research as a Strategic Tool for Preparedness and Decision-Making in Disasters

3:30pm – 4:00pm

Break/Posters/ Exhibitors

4:00pm – 5:30pm

Student Oral Session II

7:00pm – 9:00pm

Student Meet and Greet

Tuesday, April 112, 2020

7:30am – 8:45am

Breakfast/Posters/Exhibitors

7:30am – 1:00pm

Registration

8:45am – 10:15am

Use of External Data in Pharmacoepidemiology

10:15am – 11:00am

Break/Posters/Exhibitors

11:00am – 12:45pm

Translational collaborations between pharmacology and pharmacoepidemiology to enhance real-world evidence

12:45pm – 1:00pm

Closing Remarks

×

ISPE Mid-Year 2020: Session Info

Saturday, April 109, 2020
8:30am – 12:00pm

Strategic Planning Committee

Event by invitation only.

Saturday, April 109, 2020
1:00pm – 5:00pm

ISPE Board of Directors Meeting

Event open to all ISPE members

Saturday, April 109, 2020
6:00pm – 9:00pm

Board of Directors Dinner

Event by invitation only.

Sunday, April 110, 2020
7:00am – 5:00pm

Registration

Presenters:

• Sperati, Shannon

Sunday, April 110, 2020
8:00am – 12:00pm

Introduction to Pharmacoepidemiology

Room: Banda Sea 1

Ticket required.

This course will provide participants with a succinct introduction to the basic principles, concepts, and study designs of pharmacoepidemiology.

In this course, you will learn:

• How to appreciate the basic features of the cohort design and its application in pharmacoepidemiology.
• How to appreciate the basic features of the case-control design and its application in pharmacoepidemiology.
• How to recognize the basic types of bias (confounding, selection bias, measurement bias) in pharmacoepidemiological studies.
• How to understand how these biases are introduced and how they can be avoided by design or controlled during analysis.

 

Topics and Speakers:

 

Cohort Studies

Almut Winterstein, FISPE, Professor and Chair Pharmaceutical Outcomes & Policy, UF College of Pharmacy

 

Case-Control Studies

Anton Pottegård, Professor, University of Southern Denmark

 

Bias & Confounding

Yola Moride, President, YolaRx Consultants

Presenters:

• Moride, Yola
• Pottegard, Anton
• Winterstein, Almut

Sunday, April 110, 2020
8:30am – 12:00pm

2020 ICPE Scientific Program Committee

Event open to all ISPE members

Sunday, April 110, 2020
1:30pm – 5:30pm

Advanced Pharmacoepidemiology - Machine Learning in Pharmacoepidemiology

Room: Banda Sea

Ticket required.

 Moderator:

Caitlin Knox, Director of Pharmacoepidemiology, Regeneron Pharmaceuticals Inc.

 

Description:

This half-day interactive advanced pharmacoepidemiology course will cover multiple applications of machine learning approaches in pharmacoepidemiology and health outcomes research.  Each lecture will also provide the necessary framework and tools for the attendees to apply the discussed principles to their own research.

 

Advanced level: An advanced level of understanding of pharmacoepidemiology study designs, data sources, and biases are needed for this advanced-level course.

 

Topics and Speakers:

Landscape Review of Machine Learning in Pharmacovigilance

Judy Maro, Assistant Professor, Harvard Medical School

 

Identifying Health Outcomes in Automated Database Research using Machine Learning Methods

Stephan Lanes, Principal Epidemiologist, HealthCore, Inc.

 

Using Artificial Intelligence / Machine Learning for Individual Patient Predictions

Orla Doyle, Lead Data Scientist (Associate Director), IQVIA

 

Presenting and interpreting Machine Learning Results

Wei-Hsuan "Jenny" Lo-Ciganic, Assistant Professor, University of Florida

Presenters:

• Doyle, Orla
• Lanes, Stephan
• Lo-Ciganic, Jenny
• Maro, Judy

Sunday, April 110, 2020
5:30pm – 7:30pm

Welcome Reception

Room: Wantilan

Open to all ISPE members

Monday, April 111, 2020
7:30am – 5:00pm

Registration

Monday, April 111, 2020
8:15am – 9:15am

Breakfast/Posters/Exhibitors

Room: Timor Sea

Monday, April 111, 2020
9:15am – 9:30am

Welcome and Opening Remarks

Room: Banda Sea

Almut Winterstein, FISPE, ISPE President, Co-Chair, ISPE 2020 Mid-Year Planning Committee

Juan Hincapie-Castillo, Co-Chair, ISPE 2020 Mid-Year Planning Committee

Monday, April 111, 2020
9:30am – 11:30am

At the intersection of frailty and pharmacoepidemiology: Foundations, applications, and future directions

Room: Banda Sea

Moderators:

Jenny Wei, Assistant Professor, University of Florida

Scott Vouri, Clinical Assistant Professor, University of Florida

 

Description:

This symposium will provide participants with an overview of frailty as an important concept in pharmacoepidemiology. We will present aspects pertaining to measuring frailty as a clinically-relevant outcome, as well as an important confounder, or effect modifier. We will address challenges of measuring frailty from secondary data sources (i.e., claims data) in studies evaluating medication use, safety, and effectiveness in vulnerable populations.

Goals and Objectives:

The main objectives of the symposium are: (1) To provide an overview on the concept of frailty and its measurement as applied in pharmacoepidemiologic studies, (2) To discuss the challenges related to defining, identifying, and measuring frailty from different data sources in vulnerable populations, and (3) To discuss future directions in addressing existing methodological challenges in incorporating measures of frailty in pharmacoepidemiologic studies. This symposium will provide useful insights to researchers involved in or seeking additional expertise in conducting pharmacoepidemiologic studies in vulnerable populations. Participants will have the opportunity to engage in discussions with the speakers and other attendees.

 

Topics and Speakers:

5 W’s of Frailty: who, what, when, where and why

Todd Manini, Associate Professor, UF Institute on Aging, Department of Aging and Geriatric Research

 

You may know frailty when you see it, but how do you measure it?

Daniela Moga, Associate Professor, Department of Pharmacy Practice and Science, UK College of Pharmacy

 

How to Incorporate Frailty in Pharmacoepidemiology, in Just 5 Applications

Andrew Zullo, Assistant Professor of Health Services, Policy and Practice, Assistant Professor of Epidemiology

 

Current Methodological Challenges and Future Directions for Frailty Measurement in Pharmacoepidemiology

Jennifer Lund, Associate Professor, UNC Department of Epidemiology

Presenters:

• Lund, Jennifer
• Manini, Todd
• Moga, Daniela
• Zullo, Andrew

Monday, April 111, 2020
11:30am – 12:00pm

Break/Posters/Exhibitors

Room: Timor Sea

Monday, April 111, 2020
12:00pm – 1:00pm

Deprescribing and Pharmacoepidemiology - Opportunity, Power, Humility (Keynote)

Room: Banda Sea

Dr. Michael Steinman, University of California, San Francisco

Dr. Steinman is Professor of Medicine in the Division of Geriatrics at the University of California, San Francisco and the San Francisco VA Medical Center.  He is a national leader in identifying and improving the quality of medication prescribing in clinically complex older adults, while also maintaining an active clinical practice in the geriatrics clinic and inpatient general medicine service at the San Francisco VA Medical Center. Dr. Steinman's research program focuses on improving how doctors prescribe medications for older adults, and is supported by grants from the National Institutes of Health and other funders  He also has a strong interest in mentorship and supporting career development for junior investigators.

Dr. Steinman is co-Principal Investigator of the US Deprescribing Research Network, an NIH-funded national research network for research on deprescribing medications in older adults.  He also has leadership roles with several national organizations, including as co-chair of the American Geriatrics Society Beers Criteria guideline panel.  Locally, he serves as Associate Director of the UCSF Pepper Center for Aging Research; Associate Director for the UCSF National Clinician Scholars Program; Director of UCSF’s T32 Aging Research Fellowship; and is Interim Director of Research at the San Francisco Campus for Jewish Living.

Presenters:

• Steinman, Michael

Monday, April 111, 2020
1:00pm – 2:00pm

Lunch/Posters/ Exhibitors

Room: Timor Sea

Monday, April 111, 2020
2:00pm – 3:30pm

Student Oral Session I

Room: Gardenia 2

Moderators:

Elle Saine, Co-Chair, ISPE Student Council, University of Pennsylvania

Huifeng Yun, Associate Professor, University of Alabama at Birmingham

 

Presentations:

 

Description of Inappropriateness of Chronic Polypharmacy: A Nationwide Cohort Study

Jordan Guillot, University of Bordeaux

 

Evidence-Based Frameworks for the Evaluation of FDA Risk Evaluation and Mitigation Strategies (REMS): A Content Analysis of REMS Assessment Plans (2014-2018) Using RE-AIM, PRECEDE-PROCEED, and CFIR

Linda Huynh, Johns Hopkins Bloomberg School of Public health

 

Anticoagulants and the Incidence of Cancer among Individuals with Non-Valvular Atrial Fibrillation

Devin Abrahami, McGill University          

 

Influenza Vaccination among Frail Older Adults Receiving Post-Acute and Long-Term Care

Elliott Bosco, Brown University

           

The Association between Medication Adherence Patterns in Older Community-Dwelling People with Multimorbidity and Health-Related Quality of Life

Caroline Walsh, Royal College of Surgeons in Ireland

 

Identifying Unknown Diabetogenic Drugs in Nation-Wide Data: A Hypothesis-Free Screening Study

Lars Christian Lund, University of Southern Denmark 

 

Monday, April 111, 2020
2:00pm – 3:30pm

Using Drug Utilization Research as a Strategic Tool for Preparedness and Decision-Making in Disasters

Room: Banda Sea

Moderators:

Maribel Salas, Executive Director Daiichi Sankyo Incorporation/ University of Pennsylvania Perelman School of Medicine

 

Description

This symposium will focus on disasters in different settings. The session will bring forth experiences in DUR after these disasters in order to present how research was strategic in helping the health system to prepare and to respond.

Disasters are events that cause disruption in society, in many cases, leading to human losses, injuries or illnesses that may exceed the response capacity of local health services. Medicines are essential to support health care. Because of a disaster, the need to treat acute conditions such as trauma and infectious diseases is widely recognized. Nevertheless, the continuity of care for no communicable diseases (NCDs) such as cardiovascular disease, cancer, diabetes, and hypertension is also a challenge, when disasters strike. In the recovery phase, other medicines should be considered, for example, as means to support mental health care. Preparedness of pharmaceutical services will be based on data from previous events. Drug utilization research (DUR) can provide such information including the surplus need related to different types of disasters. There is urgent need to identify and develop DUR to support preparedness for disasters in order to make appropriate decisions.

Goals and Objectives:

The objective of this symposium is to discuss how DUR can be used to determine drug utilization patterns and profiles after major disasters, in order to contribute to health services and systems preparedness, to provide for and make decisions to support emerging health needs for affected populations in MIC.

 

Topics and Speakers:

 

Key challenges for DUR: can DUR help explain trends in medicine consumption after major disasters?

Claudia Osorio-de-Castro, Professor Escola Nacional de Saúde Pública – Fundação Oswaldo Cruz

 

Psychoactive drug consumption after mine tailings mudslides in MG, Brazil

Elaine Miranda, Professor Universidade Federal Fluminense

 

Drug Utilization in hospital contexts during health emergencies

Jessica Tonder, Mercy Hospital – Allina Health

 Disaster aftermath experience in Ecuador

Ivan Moya C, International Liason Ecuadorian Red Cross

Presenters:

• Garcia Serpa Osorio de Castro, Claudia
• Miranda, Elaine
• Moya Cabezas, Ivan
• Tonder, Jessica

Monday, April 111, 2020
3:30pm – 4:00pm

Break/Posters/ Exhibitors

Room: Timor Sea

Monday, April 111, 2020
4:00pm – 5:30pm

Student Oral Session II

Room: Gardenia 2

Moderators:

Caroline Walsh, Chair, ISPE Student Council, Royal College of Surgeons in Ireland

Juan Hincapie-Castillo, Assistant Professor, University of Florida, College of Pharmacy

Presentations:

Repeating Greedy Nearest Neighbor Caliper Propensity Score Matching in the Same Cohort Can Yield Highly Inconsistent Estimates of the Exposure-Outcome Association - A Simulation Study

Joris Komen, Utrecht University   

           

The Impact of Statin Use Prior To Intensive Care Unit (ICU) Admission on Sepsis-Related Mortality and Length of Stay among Patients with Sepsis

Eric Chinaeke, University of South Carolina

 

The Weight-Lowering Effects of Glucagon-Like Peptide-1 Receptor Agonists and the Detection of Breast Cancer among Women with Type 2 Diabetes

Christina Santella, McGill University       

 

Effect of Enzyme-Inducing Antiepileptic Drugs on Failure of Oral Low-Dose Hormonal Contraceptives

Amir Sarayani, University of Florida

 

Prevalence of Time-Related Biases in Pharmacoepidemiology Studies Of Anti-Emetics, Antifungal, and Antibiotic Medications during Pregnancy: A Systematic Review

Ugochinyere Vivian Ukah, McGill University      

 

Perinatal Outcomes Associated With Marijuana Use during Pregnancy

Alexandra Sosinsky, Harvard T.H. Chan School of Public Health

 

 

Monday, April 111, 2020
7:00pm – 9:00pm

Student Meet and Greet

Event organized by ISPE Student Council. All student members are invited to attend.

Tuesday, April 112, 2020
7:30am – 8:45am

Breakfast/Posters/Exhibitors

Room: Timor Sea

Tuesday, April 112, 2020
7:30am – 1:00pm

Registration

Tuesday, April 112, 2020
8:45am – 10:15am

Use of External Data in Pharmacoepidemiology

Room: Banda Sea

 

Moderator:

Til Stürmer, FISPE, Distinguished Professor and Chair, Department of Epidemiology, University of North Carolina at Chapel Hill

Background:

The inherent limitations of the available data is one of the principal problems in pharmacoepidemiologic studies. Multiple methods have been proposed to mitigate the resulting biases (due to uncontrolled confounding, exposure and outcome misclassification). Some of the most effective tools leverage external (including: validation) data.

 

Objectives:

The aim of the session is to encourage practicing pharmacoepidemiologists to think outside of the primary data, provide an overview of methods related to external data, orient the audience to existing tools/resources available to incorporate external data, and generally encourage the audience to use external data to improve one or more aspects of the study.

Topics and Speakers:

Validation studies and data linkages

Michele Jonsson Funk, FISPE, Associate Professor, University of North Carolina at Chapel Hill

 

Methods to control for unmeasured confounding based on validation data

Olaf Klungel, Professor, FISPE, University of Utrecht

 

Multiple bias analysis based on parameters assessed in external data

Kaatje Bollaerts, Senior Biostatistician, P95

Presenters:

• Bollaerts, Kaatje
• Jonsson Funk, Michele
• Klungel, Olaf

Tuesday, April 112, 2020
10:15am – 11:00am

Break/Posters/Exhibitors

Room: Timor Sea

Tuesday, April 112, 2020
11:00am – 12:45pm

Translational collaborations between pharmacology and pharmacoepidemiology to enhance real-world evidence

Room: Banda Sea

Moderator: Almut Winterstein, FISPE, Professor and Chair Pharmaceutical Outcomes & Policy, UF College of Pharmacy

 

Description:

While pharmacoepidemiology aims to assess causal inference from real-world data on drug safety and effectiveness, pharmacometrics often aims to extrapolate these same findings from quantitative models to the real-world. Though we have the same overarching goals, often times opportunities for collaboration and translational research are missed. This symposium will present case studies of how collaborations between pharmacoepidemiologists using real-world data and pharmacometricians using quantitative systems pharmacology enhance and strengthen research findings and our understanding of drug effects and mechanisms.

 

Goals and Objectives:

1. Introduce basic terminology and approaches in quantitative systems pharmacology and pharmacometrics
2. Describe a conceptual framework of hypothesis generation, confirmation, and cross-validation and how this enhances research in pharmacoepidemiology and generates actionable evidence
3. Discuss case studies of research projects that demonstrate the strength of translational collaborations and implications when findings do not agree

 

Topics and Speakers:

 

Pharmacometric Approaches to Efficacy and Safety Questions: An introduction to the discipline and examples from collaborative research on generic drugs

Stephan Schmidt, Associate Professor and Director, Center for Pharmacometrics and Systems Pharmacology, UF College of Pharmacy

 

The translational tale of dicloxacillin interactions – from the registries to the petri dish and back again

Anton Pottegård, Professor, University of Southern Denmark

 

Translational Biomedical Informatics Approach to Identify Drug-drug Interactions: A Case Study of Direct-acting Oral Anticoagulants and Serious Bleeding

Meijia Zhou, Post-Doctoral Fellow, Medical Device Epidemiology, Johnson & Johnson

 

Enhancing pharmacoepidemiology and pharmacoeconomics through collaboration with pharmacometricians – examples in generic drugs and drug-drug interactions

Joshua Brown, Assistant Professor, Pharmaceutical Outcomes & Policy, UF College of Pharmacy

Presenters:

• Brown, Joshua
• Pottegard, Anton
• Schmidt, Stephan
• Zhou, Meijia

Tuesday, April 112, 2020
12:45pm – 1:00pm

Closing Remarks

Room: Banda Sea

Almut Winterstein, FISPE, ISPE President, Chair, ISPE 2020 Mid-Year Planning Committee

Close